toremifene and Thoracic-Neoplasms

toremifene has been researched along with Thoracic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for toremifene and Thoracic-Neoplasms

Article	Year
[A breast cancer patient with recurrence in the thoracic wall in whom a high-dose of toremifene was effective]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:2 The patient was a 53-year-old female who presented with a primary complaint of reddening of the left precordial skin. She had undergone mastectomy for cancer of the left breast 12 years and 4 months earlier and had received endocrine chemotherapy including TAM as a postoperative adjuvant therapy. A diagnosis of thoracic wall recurrence was made by chest CT and pathological examination of skin biopsy specimens. Toremifene (TOR) was administrated at 120 mg/day, and PR was maintained for 8 months. Even after the condition became PD, the patient has retained adequate QOL with combination therapies including radiotherapy, and is still treated on an outpatient basis 3 years after the beginning of the treatment. Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Selective Estrogen Receptor Modulators; Thoracic Neoplasms; Toremifene	2001

Article

Year

[A breast cancer patient with recurrence in the thoracic wall in whom a high-dose of toremifene was effective].

Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:2

The patient was a 53-year-old female who presented with a primary complaint of reddening of the left precordial skin. She had undergone mastectomy for cancer of the left breast 12 years and 4 months earlier and had received endocrine chemotherapy including TAM as a postoperative adjuvant therapy. A diagnosis of thoracic wall recurrence was made by chest CT and pathological examination of skin biopsy specimens. Toremifene (TOR) was administrated at 120 mg/day, and PR was maintained for 8 months. Even after the condition became PD, the patient has retained adequate QOL with combination therapies including radiotherapy, and is still treated on an outpatient basis 3 years after the beginning of the treatment.

Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Selective Estrogen Receptor Modulators; Thoracic Neoplasms; Toremifene

2001